Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and half yearly results to Dec 31, 2025. Highlights include four provisional patent filings expected to expand IP from ~90 to >200 patents, a peer‑reviewed publication on PRP in PDAC fibroblasts, and a private placement facility up to $100 million.

Financials: total assets $15.11M, convertible notes reduced to $55,000, quarter‑end cash $561,237, and initial proceeds of $1.5M received under the Series C facility.

Positive

• Private placement facility up to $100 million
• IP portfolio expected to expand from ~90 to over 200 patents
• Peer‑reviewed publication demonstrating PRP effects on PDAC fibroblasts
• Convertible notes reduced to $55,000

Negative

• Quarter‑end cash balance of only $561,237
• Received $1.5 million initial draws against the $100M facility to date

Key Figures

Private placement facility: $100 million Initial Series C investment: $1 million Follow-on Series C investment: $500,000 +5 more

8 metrics

Private placement facility $100 million Total size of private placement agreement to accelerate clinical development

Initial Series C investment $1 million Cash received for 100 shares of Series C Convertible Preferred Stock

Follow-on Series C investment $500,000 Additional cash upon exercise of 50 Series C Convertible Preferred shares

Total assets $15.11 million Quarter ended September 30, 2025

Liabilities reduction $2.07 million Decrease in total liabilities in Q1 2025/26

Convertible notes balance $55,000 Reduced from $538,000 as of quarter ended September 30, 2025

Net cash from financing $3.49 million Quarter ended September 30, 2025

Quarter-end cash $561,237 Cash balance at September 30, 2025

Market Reality Check

Price: $0.2100 Vol: Today’s volume of 1,110,6...

low vol

$0.2100 Last Close

Volume Today’s volume of 1,110,651 shares is below the 20-day average of 3,367,455 (relative volume 0.33x). low

Technical Shares at $0.2199 are trading well below the 200-day MA of $2.72 and 99.08% under the 52-week high of $24.

Peers on Argus

PPCB is up 3.24% while close peers show mixed moves: AKTX (-1.21%), LIXT (-1.95%...

1 Down

PPCB is up 3.24% while close peers show mixed moves: AKTX (-1.21%), LIXT (-1.95%), ALLR (-2.35%), BOLD (+1.77%), RNTX (+3.60% in sector list but flagged -2.57% on the momentum scanner). Overall, moves do not clearly track PPCB’s direction, indicating stock-specific trading.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	PRP spotlight	Positive	+5.7%	Highlighted PRP data, FDA orphan status and market opportunity.
Jan 27	IP expansion	Positive	+6.5%	Announced fourth provisional patent filing for proenzyme formulations.
Jan 20	Rec-PRP patent	Positive	-4.7%	Filed provisional patent for synthetic Rec‑PRP manufacturing methods.
Jan 15	PRP overview	Positive	-17.1%	Outlined PRP preclinical data and clinical plans for pancreatic cancer.
Jan 13	Shareholder update	Positive	-4.3%	Provided shareholder update on 2025 progress and 2026 clinical plans.

Pattern Detected

Recent upbeat PR and IP updates often saw negative next-day reactions, with 3 divergences vs 2 alignments.

Recent Company History

Over the last few weeks, Propanc has repeatedly highlighted PRP and Rec‑PRP progress, including IP expansion and plans for a Phase 1b first‑in‑human study in 30–40 patients, plus financing and IPO‑related updates. Some news, like the PRP spotlight on Feb 5 and IP filings on Jan 27, coincided with positive moves, while other seemingly positive IP and pipeline updates on Jan 20, Jan 15, and Jan 13 were followed by declines, showing an uneven reaction pattern to similar promotional news.

Market Pulse Summary

This announcement combines scientific progress and financing. Propanc filed four provisional patents...

Analysis

This announcement combines scientific progress and financing. Propanc filed four provisional patents that could expand its IP from about 90 to over 200 patents and published new data on the tumor microenvironment in pancreatic cancer. Financially, it outlined a $100 million private placement facility, with initial tranches and Q1 figures such as $15.11 million in assets and reduced liabilities. Investors may watch cash runway, use of the facility, and milestones for the planned Phase 1b study.

Key Terms

provisional patent, pancreatic ductal adenocarcinoma, tumor microenvironment, cancer-associated fibroblasts, +4 more

8 terms

provisional patent regulatory

"Four provisional patent applications were filed with IP Australia detailing two new methods"

A provisional patent is a temporary filing that locks in an early priority date for an invention and lets a company label the technology as "patent pending" while it develops the idea and prepares a full patent application. It matters to investors because it signals an intent to protect intellectual property with relatively low initial cost and a limited window to convert to a full patent; it can reduce the risk of being preempted by others but does not guarantee long-term legal protection.

pancreatic ductal adenocarcinoma medical

"impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts"

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

tumor microenvironment medical

"The tumor microenvironment (TME) plays a pivotal role in tumor initiation"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

cancer-associated fibroblasts medical

"containing a significant enriched population of cancer-associated fibroblasts (CAFs)"

Cells in and around tumors that act like supportive 'soil' for cancer cells, helping tumors grow, shape their environment, and often shielding them from treatments. They matter to investors because therapies or diagnostics that target these cells can change how well cancer drugs work, affect clinical trial outcomes and market potential, and serve as biomarkers that influence pricing and adoption decisions.

phase 1b medical

"preparing for our world-first, Phase 1b, First-In-Human study in advanced cancer patients"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

first-in-human medical

"Phase 1b, First-In-Human study in advanced cancer patients"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

gmp manufacturing technical

"Activities include partnering with GMP manufacturing and bio-analytical contract organizations"

GMP manufacturing, or Good Manufacturing Practice, is a set of strict guidelines that ensure products, especially medicines and health-related items, are consistently produced and controlled to meet quality standards. For investors, it signifies that a company follows high-quality processes, reducing risks of defects or contamination, which can impact product safety and market trust. This adherence helps ensure the reliability and reputation of the products in the marketplace.

pharmacokinetics medical

"validate the pharmacokinetics method for the upcoming pivotal study"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

AI-generated analysis. Not financial advice.

MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported half yearly financial results as of December 31, 2025 (Year end June 30).

Corporate and R&D Highlights

Accelerates IP Momentum: Files Four Provisional Patent Applications – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Four provisional patent applications were filed with IP Australia detailing two new methods to treat resistant cancer and fibrosis, methods of producing synthetic trypsinogen and chymotrypsinogen, and innovative formulations of trypsinogen and chymotrypsinogen. As these applications advance to national phase entry across major global markets, it is expected to more than double the Company’s IP portfolio — from approximately 90 to over 200 patents — covering compositions, formulations, treatment methods, and new therapeutic indications

Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

The Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer reviewed journal, Scientific Reports, regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The tumor microenvironment (TME) plays a pivotal role in tumor initiation, progression, and the form of pre-metastatic niches. PDAC is characterized by a dense fibrotic stroma containing a significant enriched population of cancer-associated fibroblasts (CAFs). The interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis, underscoring the potential benefits of novel therapeutic strategies targeting stromal cells to improve patient survival. PRP, consisting of two bovine derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, have shown efficacy in cancer treatment. The findings demonstrate PRP exerts multifaceted effects. Results underscore the candidacy of PRP as a potential disruptor of the TME.

Corporate and Financial Updates

$100 Million Private Placement Facility

Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1 million investment upon issuance of 100 shares of Series C Convertible Preferred Stock. A further $500,000 investment was received upon exercise of 50 shares of Series C Convertible Preferred Stock.

Q1 Financial Summary (Quarter Ended September 30, 2025)

• Total assets: $15.11 million
• Total liabilities reduced by $2.07 million
• Convertible notes reduced to $55,000 (from $538,000)
• Net cash from financing activities: $3.49 million
• Quarter-end cash: $561,237
• $0.5 million tranche from the Series C facility subsequently received

The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.

Management Commentary

“We are pleased with the advancements made with our R&D programs and in particular, our lead asset PRP which we are preparing for our world-first, Phase 1b, First-In-Human study in advanced cancer patients,” said James Nathanielsz, CEO of Propanc. “We are executing several activities in preparation for this pivotal study, which we believe will become a future breakthrough treatment for metastatic cancer from solid tumors, especially fast spreading tumors with a poor patient prognosis where few treatment options exist. Activities include partnering with GMP manufacturing and bio-analytical contract organizations to produce the drug product and validate the pharmacokinetics method for the upcoming pivotal study. In the meantime, we continue to build the foundation for sustained success by extending our scientific research through partner universities, which enables further patentable discoveries including new therapeutic indications that could elevate proenzyme technology to future blockbuster status.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
		December 31, 2025				June 30, 2025
		(Unaudited)
ASSETS
CURRENT ASSETS:
Cash		$	561,237			$	12,088
GST tax receivable			16,994				5,302
Prepaid expenses - current portion			7,127,293				8,334,046
Other current assets			1,400				1,380
TOTAL CURRENT ASSETS			7,706,924				8,352,816
Deferred offering costs			-				291,773
Prepaid expenses - long-term portion			7,347,310				10,925,835
Security deposit - related party			2,000				1,971
Operating lease right-of-use assets, net - related party			50,901				59,413
Property and equipment, net			4,397				-
TOTAL ASSETS		$	15,111,532			$	19,631,808
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	957,483			$	1,249,596
Accrued expenses and other payables			860,463				1,486,550
Accrued interest			168,152				190,795
Loans payable			65,280				65,280
Loans payable - related parties, net of discount			472,083				415,329
Notes payable, net of discount			-				543,312
Convertible notes, net of discounts and including put premiums			55,000				537,921
Operating lease liability - related party, current portion			21,604				17,664
Warrant liability			288,635				-
Embedded conversion option liabilities			32,128				403,892
Employee benefit liability			703,190				667,901
TOTAL CURRENT LIABILITIES			3,624,018				5,578,240
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount			-				105,627
Operating lease liability - long-term portion - related party			35,249				41,749
TOTAL NON-CURRENT LIABILITIES			35,249				147,376
TOTAL LIABILITIES		$	3,659,267			$	5,725,616
Temporary Equity – Convertible Preferred Stock Series C - $0.01 par value, $10,000 stated value, 9,900 shares designated and authorized, 100 (liquidation value of $1,000,000) and none issued and outstanding at December 31, 2025 and June 30, 2025, respectively		$	1,000,000			$	-
Commitments and Contingencies (See Note 9)			-				-
STOCKHOLDERS’ EQUITY:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of December 31, 2025 and June 30, 2025		$	-			$	-
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of December 31, 2025 and June 30, 2025			-				-
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 13,449,688 and 11,611,782 shares issued and outstanding as of December 31, 2025 and June 30, 2025, respectively			13,450				11,612
Common stock issuable (7,750 and 7,750 shares as of December 31, 2025 and June 30, 2025, respectively)			8				8
Additional paid-in capital			143,640,067				138,243,652
Accumulated other comprehensive income			1,328,115				1,318,917
Accumulated deficit			(134,482,898	)			(125,621,520	)
Treasury stock ($0.001 share)			(46,477	)			(46,477	)
TOTAL STOCKHOLDERS’ EQUITY			10,452,265				13,906,192
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	15,111,532			$	19,631,808

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
		For the three months ended December 31,								For the six months ended December 31,
		2025				2024				2025				2024
REVENUE
Revenue		$	-			$	-			$	-			$	-
OPERATING EXPENSES
Administration expenses			3,628,173				153,593				8,226,747				374,352
Occupancy expenses - related party			6,600				5,401				21,389				13,718
Research and development			19,961				54,388				80,162				116,102
TOTAL OPERATING EXPENSES			3,654,734				213,382				8,328,298				504,172
LOSS FROM OPERATIONS			(3,654,734	)			(213,382	)			(8,328,298	)			(504,172	)
OTHER INCOME (EXPENSE)
Interest expense			(58,955	)			(118,943	)			(364,604	)			(205,173	)
Interest income			37				-				56				1
Derivative expense			-				(8,559	)			-				(35,741	)
Change in fair value of derivative liabilities			87,728				13,581				68,022				66,368
Change in fair value of warrant liability			593,710				-				593,710				-
Other expense			(54,000	)			-				(54,000	)			-
Gain (loss) on extinguishment of debt, net			14,317				(18,759	)			210,178				(30,078	)
Foreign currency transaction gain (loss)			(19,497	)			(84,121	)			(54,196	)			(75,698	)
TOTAL OTHER INCOME (EXPENSE), NET			563,340				(216,801	)			399,166				(280,321	)
LOSS BEFORE TAXES			(3,091,394	)			(430,183	)			(7,929,132	)			(784,493	)
Tax benefit			-				-				-				-
NET LOSS		$	(3,091,394	)		$	(430,183	)		$	(7,929,132	)		$	(784,493	)
Deemed Dividend			(932,246	)			-				(932,246	)			-
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS		$	(4,023,640	)		$	(430,183	)		$	(8,861,378	)		$	(784,493	)
BASIC AND DILUTED NET LOSS PER SHARE		$	(0.30	)		$	(32.23	)		$	(0.69	)		$	(67.65	)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING			13,360,358				13,347				12,848,520				11,597
NET LOSS		$	(4,023,640	)		$	(430,183	)		$	(8,861,378	)		$	(784,493	)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)			(7,846	)			321,230				9,198				222,287
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)			(7,846	)			321,230				9,198				222,287
TOTAL COMPREHENSIVE LOSS		$	(4,031,486	)		$	(108,953	)		$	(8,852,180	)		$	(562,206	)

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

FAQ

What does Propanc (PPCB) filing four provisional patents mean for investors?

It signals meaningful IP expansion and potential commercial protection for proenzyme assets. According to the company, filings could increase the IP portfolio from ~90 to over 200 patents, covering formulations and treatment methods that may strengthen long‑term value.

How much funding has Propanc (PPCB) secured from the new private placement facility?

The company established a facility of up to $100 million and has drawn initial proceeds. According to the company, Propanc received $1 million for 100 Series C shares and a further $500,000 on exercise, totaling $1.5 million.

What were Propanc's key balance sheet figures for the quarter ended Sept 30, 2025?

Key figures include total assets of $15.11 million and quarter‑end cash of $561,237. According to the company, total liabilities fell by $2.07 million and convertible notes were reduced to $55,000.

What did the peer‑reviewed study report about PRP and pancreatic cancer fibroblasts?

The study reported multifaceted effects of PRP on PDAC fibroblasts that may disrupt the tumor microenvironment. According to the company, findings support PRP’s candidacy as a potential TME‑targeting therapeutic in PDAC research.

Is Propanc (PPCB) preparing for human clinical trials of PRP?

Yes, the company is preparing a Phase 1b First‑In‑Human study in advanced cancer patients. According to the company, activities include GMP manufacturing partnerships and bioanalytical method validation ahead of the pivotal study.

How reliant is Propanc (PPCB) on the Series C facility for near‑term R&D funding?

Propanc expects the facility to support planned R&D, but initial draws remain modest. According to the company, the $100 million facility is intended to continually support advancement of PRP and Rec‑PRP programs.